- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Microfluidic devices, essentially miniaturized chemical laboratories etched into material similar to a microprocessor chip, are revolutionizing diagnostic medicine by providing a technology platform that is more sensitive and less expensive than conventional analytical technologies. A new sensing method that relies on nanoscale holes drilled into a microfluidic device also could add "faster" to the list of benefits afforded by microfluidics.
Reporting their work in the journal Analytical Chemistry, researchers at the University of British Columbia created a grid of 30 x 30 flow-through nanoscale holes to create a highly responsive sensor system that can detect biomolecules of interest without requiring the additional use of an optical label. They used a tightly focused laser to drill holes through a 100-nanometer-thick layer of gold deposited on a 100-nanometer-thick slab of silicon nitride. The resulting sensor array then was integrated into a microfluidic chip made of poly(dimethylsiloxane), a standard material used to make lab-on-a-chip devices for biomedical applications.
With the array in hand, the investigators then attached a monoclonal antibody to the gold lining inside the holes. This monoclonal antibody binds to a cancer biomarker protein known as PAX8. The researchers then took advantage of an optical phenomenon known as surface plasmon resonance (SPR), which takes place on thin films of gold. When irradiated with laser light, thin gold films will emit a sharp, bright burst of light whose wavelength changes as various molecules stick to the gold surface. In this case, the SPR signal changed whenever PAX8 bound to the antibody attached to the gold film lining the array holes. When compared with established SPR-based measurement techniques, the flow-through device had a response time that was sixfold faster while measuring PAX8 present at concentrations in the attomolar range.
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Droplets finally all the same size -- in a nanodroplet library June 20th, 2016
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Drum beats from a one atom thick graphite membrane June 15th, 2016